Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People’s Republic of China

Cheng Rang Li, Qiu Xia Mao, Min Chen, Wei Xue Jia, Xu Yao, Su Ying Feng, Hong Jia, Juan Qin Gong, Xue Yuan Yang

Research output: Contribution to journalArticle

Abstract

Background: TNF-α plays a key role in host defense against mycobacterial infection, and patients receiving TNF-α blocker treatment have increased susceptibility to tuberculosis disease. In the People’s Republic of China, an intermediate tuberculosis-burden country, the latent tuberculosis infection (LTBI) risk in patients with psoriasis who are treated with etanercept, the safest kind of TNF-α blocker, is unknown. Objectives: This study reports the LTBI risk in patients with psoriasis after etanercept treatment and aims to answer the question of how often rescreening for LTBI should be done in order to reduce active tuberculosis infection of patients and further reduce the incidence of active tuberculosis disease. Patients and methods: This retrospective review evaluated patients with moderate-to-severe chronic plaque psoriasis between 2009 and 2013. All patients were excluded tuberculosis infection and received etanercept 25 mg twice weekly, then the patients were checked for LTBI 3 months after etanercept treatment to observe the incidence of LTBI and assess the need for rescreening for LTBI every 3 months. Results: We retrospectively analyzed 192 patients with psoriasis with moderate-to-severe chronic plaque whose tuberculin skin test and chest X-rays were negative and who received etanercept 25 mg twice weekly. Eighteen of them were excluded because they received less than 3 months of etanercept therapy. After treatment with etanercept, four patients were found to have LTBI. Conclusion: In this study, the incidence of LTBI after 3 months was four in 192 (2.1%), which is higher than the annual incidence of LTBI in the People’s Republic of China (0.72%), so LTBI could be expected to occur within 3 months in psoriasis patients on etanercept. Periodic screening for LTBI in the therapy course, as well as before initiating treatment, is necessary in those patients who use a TNF-α blocker. We recommend rescreening for LTBI every 3 months.

Original languageEnglish (US)
Pages (from-to)5591-5594
Number of pages4
JournalDrug Design, Development and Therapy
Volume9
DOIs
StatePublished - Oct 12 2015
Externally publishedYes

Fingerprint

Latent Tuberculosis
Psoriasis
China
Tuberculosis
Therapeutics
Etanercept
Incidence
Infection
Tuberculin Test
Skin Tests

Keywords

  • Fusion protein
  • LTBI
  • TB screening
  • TNF receptor
  • TNFR
  • Treatment

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People’s Republic of China. / Li, Cheng Rang; Mao, Qiu Xia; Chen, Min; Jia, Wei Xue; Yao, Xu; Feng, Su Ying; Jia, Hong; Gong, Juan Qin; Yang, Xue Yuan.

In: Drug Design, Development and Therapy, Vol. 9, 12.10.2015, p. 5591-5594.

Research output: Contribution to journalArticle

Li, Cheng Rang ; Mao, Qiu Xia ; Chen, Min ; Jia, Wei Xue ; Yao, Xu ; Feng, Su Ying ; Jia, Hong ; Gong, Juan Qin ; Yang, Xue Yuan. / Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People’s Republic of China. In: Drug Design, Development and Therapy. 2015 ; Vol. 9. pp. 5591-5594.
@article{15e6d14babee42f0846c22cba29d9206,
title = "Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People’s Republic of China",
abstract = "Background: TNF-α plays a key role in host defense against mycobacterial infection, and patients receiving TNF-α blocker treatment have increased susceptibility to tuberculosis disease. In the People’s Republic of China, an intermediate tuberculosis-burden country, the latent tuberculosis infection (LTBI) risk in patients with psoriasis who are treated with etanercept, the safest kind of TNF-α blocker, is unknown. Objectives: This study reports the LTBI risk in patients with psoriasis after etanercept treatment and aims to answer the question of how often rescreening for LTBI should be done in order to reduce active tuberculosis infection of patients and further reduce the incidence of active tuberculosis disease. Patients and methods: This retrospective review evaluated patients with moderate-to-severe chronic plaque psoriasis between 2009 and 2013. All patients were excluded tuberculosis infection and received etanercept 25 mg twice weekly, then the patients were checked for LTBI 3 months after etanercept treatment to observe the incidence of LTBI and assess the need for rescreening for LTBI every 3 months. Results: We retrospectively analyzed 192 patients with psoriasis with moderate-to-severe chronic plaque whose tuberculin skin test and chest X-rays were negative and who received etanercept 25 mg twice weekly. Eighteen of them were excluded because they received less than 3 months of etanercept therapy. After treatment with etanercept, four patients were found to have LTBI. Conclusion: In this study, the incidence of LTBI after 3 months was four in 192 (2.1{\%}), which is higher than the annual incidence of LTBI in the People’s Republic of China (0.72{\%}), so LTBI could be expected to occur within 3 months in psoriasis patients on etanercept. Periodic screening for LTBI in the therapy course, as well as before initiating treatment, is necessary in those patients who use a TNF-α blocker. We recommend rescreening for LTBI every 3 months.",
keywords = "Fusion protein, LTBI, TB screening, TNF receptor, TNFR, Treatment",
author = "Li, {Cheng Rang} and Mao, {Qiu Xia} and Min Chen and Jia, {Wei Xue} and Xu Yao and Feng, {Su Ying} and Hong Jia and Gong, {Juan Qin} and Yang, {Xue Yuan}",
year = "2015",
month = "10",
day = "12",
doi = "10.2147/DDDT.S87260",
language = "English (US)",
volume = "9",
pages = "5591--5594",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People’s Republic of China

AU - Li, Cheng Rang

AU - Mao, Qiu Xia

AU - Chen, Min

AU - Jia, Wei Xue

AU - Yao, Xu

AU - Feng, Su Ying

AU - Jia, Hong

AU - Gong, Juan Qin

AU - Yang, Xue Yuan

PY - 2015/10/12

Y1 - 2015/10/12

N2 - Background: TNF-α plays a key role in host defense against mycobacterial infection, and patients receiving TNF-α blocker treatment have increased susceptibility to tuberculosis disease. In the People’s Republic of China, an intermediate tuberculosis-burden country, the latent tuberculosis infection (LTBI) risk in patients with psoriasis who are treated with etanercept, the safest kind of TNF-α blocker, is unknown. Objectives: This study reports the LTBI risk in patients with psoriasis after etanercept treatment and aims to answer the question of how often rescreening for LTBI should be done in order to reduce active tuberculosis infection of patients and further reduce the incidence of active tuberculosis disease. Patients and methods: This retrospective review evaluated patients with moderate-to-severe chronic plaque psoriasis between 2009 and 2013. All patients were excluded tuberculosis infection and received etanercept 25 mg twice weekly, then the patients were checked for LTBI 3 months after etanercept treatment to observe the incidence of LTBI and assess the need for rescreening for LTBI every 3 months. Results: We retrospectively analyzed 192 patients with psoriasis with moderate-to-severe chronic plaque whose tuberculin skin test and chest X-rays were negative and who received etanercept 25 mg twice weekly. Eighteen of them were excluded because they received less than 3 months of etanercept therapy. After treatment with etanercept, four patients were found to have LTBI. Conclusion: In this study, the incidence of LTBI after 3 months was four in 192 (2.1%), which is higher than the annual incidence of LTBI in the People’s Republic of China (0.72%), so LTBI could be expected to occur within 3 months in psoriasis patients on etanercept. Periodic screening for LTBI in the therapy course, as well as before initiating treatment, is necessary in those patients who use a TNF-α blocker. We recommend rescreening for LTBI every 3 months.

AB - Background: TNF-α plays a key role in host defense against mycobacterial infection, and patients receiving TNF-α blocker treatment have increased susceptibility to tuberculosis disease. In the People’s Republic of China, an intermediate tuberculosis-burden country, the latent tuberculosis infection (LTBI) risk in patients with psoriasis who are treated with etanercept, the safest kind of TNF-α blocker, is unknown. Objectives: This study reports the LTBI risk in patients with psoriasis after etanercept treatment and aims to answer the question of how often rescreening for LTBI should be done in order to reduce active tuberculosis infection of patients and further reduce the incidence of active tuberculosis disease. Patients and methods: This retrospective review evaluated patients with moderate-to-severe chronic plaque psoriasis between 2009 and 2013. All patients were excluded tuberculosis infection and received etanercept 25 mg twice weekly, then the patients were checked for LTBI 3 months after etanercept treatment to observe the incidence of LTBI and assess the need for rescreening for LTBI every 3 months. Results: We retrospectively analyzed 192 patients with psoriasis with moderate-to-severe chronic plaque whose tuberculin skin test and chest X-rays were negative and who received etanercept 25 mg twice weekly. Eighteen of them were excluded because they received less than 3 months of etanercept therapy. After treatment with etanercept, four patients were found to have LTBI. Conclusion: In this study, the incidence of LTBI after 3 months was four in 192 (2.1%), which is higher than the annual incidence of LTBI in the People’s Republic of China (0.72%), so LTBI could be expected to occur within 3 months in psoriasis patients on etanercept. Periodic screening for LTBI in the therapy course, as well as before initiating treatment, is necessary in those patients who use a TNF-α blocker. We recommend rescreening for LTBI every 3 months.

KW - Fusion protein

KW - LTBI

KW - TB screening

KW - TNF receptor

KW - TNFR

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84944745819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944745819&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S87260

DO - 10.2147/DDDT.S87260

M3 - Article

C2 - 26508833

AN - SCOPUS:84944745819

VL - 9

SP - 5591

EP - 5594

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -